Geode Capital Management LLC Purchases 50,961 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Geode Capital Management LLC grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,326,794 shares of the company's stock after buying an additional 50,961 shares during the period. Geode Capital Management LLC owned 2.69% of Prestige Consumer Healthcare worth $95,678,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC raised its stake in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after purchasing an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after buying an additional 433 shares in the last quarter. nVerses Capital LLC raised its position in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock valued at $43,000 after buying an additional 400 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after acquiring an additional 181 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Prestige Consumer Healthcare by 106.9% during the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company's stock worth $63,000 after acquiring an additional 448 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Insider Activity at Prestige Consumer Healthcare

In related news, insider William P'pool sold 8,987 shares of the company's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. Insiders own 1.60% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Wednesday. DA Davidson reaffirmed a "buy" rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.25.

Prestige Consumer Healthcare Trading Up 0.1 %

PBH traded up $0.06 during trading on Friday, reaching $78.72. 604,977 shares of the company's stock were exchanged, compared to its average volume of 253,877. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a one year low of $57.95 and a one year high of $86.36. The firm has a fifty day moving average price of $79.25 and a two-hundred day moving average price of $73.04. The stock has a market capitalization of $3.89 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period last year, the company earned $1.07 EPS. Prestige Consumer Healthcare's revenue for the quarter was down .9% compared to the same quarter last year. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.